Corvus Pharmaceuticals CRVS Ratios & Valuation
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Returns | ||||||
| Return on equity | -30.5%+69.7pp | -32.6%+142pp | -35.8%+165pp | -68.7%-23.8pp | -100.1%-39.7pp | |
| Return on invested capital | -38.8%+47.4pp | -104.2%+1.0pp | -99.6%+48.2pp | -68.5%-10.7pp | -86.2%-18.8pp | |
| Liquidity | ||||||
| Current ratio | 19.8×+14.9× | 6.2×+4.7× | 8.3×+7.4× | 8.9×+5.3× | 4.9×+1.5× | |
| Leverage | ||||||
| Debt-to-equity | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | |
| Per Share | ||||||
| Book value per share | $2.67+307% | $0.77+43.7% | $0.87+366% | $1.03+20.2% | $0.66-3.5% | |
| Valuation | ||||||
| Market capitalization | $1.1B+259% | $575.05M+67.3% | $549.17M+66.3% | $334.68M+194% | $216.67M+148% | |
| Price / book | 4.6×-1.6× | 9.4×-1.2× | 7.7×-19.0× | 4.2×+1.9× | 4.4×+1.8× |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where do Corvus Pharmaceuticals's ratios come from?
- Every ratio is computed from Corvus Pharmaceuticals's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.